Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/ Phase 2 Study Evaluating the Safety and Efficacy of the Investigational New Drug TTHX1114(NM141) on the Regeneration of Corneal Endothelial Cells in Patients With Corneal Endothelial Dystrophies Following Intracameral Delivery

NCT04520321 is registered in ClinicalTrials.gov with Trefoil Therapeutics, Inc. as lead sponsor.

NCT NCT04520321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04520321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/ Phase 2 Study Evaluating the Safety and Efficacy of the Investigational New Drug TTHX1114(NM141) on the Regeneration of Corneal Endothelial Cells in Patients With Corneal Endothelial Dystrophies Following Intracameral Delivery
Lead sponsor
Trefoil Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 19, 2020
Completion date
May 18, 2021
Enrollment
22 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

corneal endothelial dystrophy, endothelial dysfunction, fuchs endothelial corneal dystrophy, pseudophakic bullous keratopathy